Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613470 · ClinicalTrials.gov registry record · Phase 1
Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 927
- Enrollment target
NCT00613470: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00613470 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 927 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1445% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00613470, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 927 participants
- Enrollment target
Study Summary
This study is one component of a larger U01 grant that was submitted in August, 2004 to the NIGMS as part of the Pharmacogenomic Research Network. This study will enroll 1200 patients over 4 years. It is known that functionally significant genetic polymorphisms for the cytochrome P450 (CYPs) can contribute to individual differences in response to specific selective serotonin reuptake inhibitors (SSRIs). However, a better understanding of the pharmacogenomics of both PK and PD for SSRI antidepressants will inform clinical practice. Therefore, we propose to evaluate the contribution of pharmacogenomics to variation in response to the highly specific SSRIs citalopram (a racemic mixture) and escitalopram (a chiral compound containing the active S-isomer of citalopram ) by correlating both PK and PD variation for these agents with intragene haplotypes in genes encoding proteins involved in citalopram metabolism, as well as central nervous system (CNS) pathways for monoamine neurotransmitter biosynthesis, metabolism, storage, release, reuptake, and receptors. In the future this "candidate pathway" intragene haplotype genotyping strategy will also be complemented by the application of genome-wide screens performed with DNA from subjects with extreme phenotypes for response to citalopram. Phenotypes to be measured before and after the initiation of citalopram or escitalopram therapy will include determinations of serum citalopram and metabolite concentrations, treatment response as measured by Hamilton Rating Scale for Depression indices, and number and severity of side effects as determined by structured questionnaires. The hypothesis to be tested is that inherited variation in citalopram metabolism and transport (PK) and/or PD variation as a result of inherited variation in monoamine neurotransmitter biosynthesis, metabolism, reuptake, storage, receptors or signaling contribute to individual variation in citalopram antidepressant efficacy and/or side effects.
Interventions
- DRUG citalopram and escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 927 participants |
| Start Date | 2005-03 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
What the finished NCT00613470 record still lists
NCT00613470 is an interventional study that assigns participants to a tested intervention. The registered 927 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1445% higher).
The record links to 0 conditions, and to 1 intervention - of which citalopram and escitalopram is the first listed.
NCT00613470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00613470 about?
NCT00613470 is a clinical study titled "Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram". This study is one component of a larger U01 grant that was submitted in August, 2004 to the NIGMS as part of the Pharmacogenomic Research Network. This study will enroll 1200 patients over 4 years. It is known that functionally significant genetic polymorphisms for the cytochrome P450 (CYPs) can co...
What is the current status of trial NCT00613470?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 927 participants. The study started on 2005-03. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00613470?
The interventions under investigation include: citalopram and escitalopram (DRUG).
Who is sponsoring clinical trial NCT00613470?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00613470's enrollment target sits among peer trials
927 10th of 2000 higher than 1,991 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06378541 · 928 participants · NA
Smartphone App Enhanced Facilitation Among Veterans in a Mental Health Inpatient Setting (Project HOPE)
- NCT06555029 · 929 participants · NA
Oral Health Intervention in Adult Primary Care
- NCT03995082 · 925 participants · NA
Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia